CYP51A1 (Lanosterol 14-alpha demethylase) variants and mutations
CYP51A1 (also known as Lanosterol 14-alpha demethylase) is a human protein-coding gene encoding a lanosterol 14-alpha demethylase protein. A cytochrome P450 enzyme in the cholesterol-biosynthesis pathway. It removes a methyl group from lanosterol and related sterols, creating intermediates needed to make cholesterol and downstream steroid-related molecules. This analysis covers 761 CYP51A1 variants and mutations. Of these, 97% have computational variant effect predictions. Disease context includes Developmental cataract, early-onset non-syndromic cataract, and cataract. Example CYP51A1 variants include A2P, A2V, and A3V.
Variant analysis overview
- Gene: CYP51A1
- Protein: Lanosterol 14-alpha demethylase
- UniProt accession: Q16850
- Organism: Homo sapiens
- Variants analyzed: 761
- Variant scope: all variants
- Completed: 2026-07-17
Variant and mutation evidence
- Variant composition: 507 unspecified-consequence records; 2 stop retained variant; 2 stop lost; 84 synonymous variants; 125 missense variants; 6 splice-region variants; 26 frameshift variants; 6 stop-gained variants; 1 in-frame deletions; 1 in-frame insertions; 1 substitution
- Prediction scores: 736 variants have prediction scores (97% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: Developmental cataract, early-onset non-syndromic cataract, cataract, Prolonged QT interval, neurodegenerative disease, long QT syndrome 11, Abnormality of the cardiovascular system, long QT syndrome 1, cardiac arrest, Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy, breast carcinoma.
Protein structure and variant hotspots
- Protein features: 1 transmembrane segments; 1 binding sites.
- Structural context: 26 variants have structural context.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, PharmGKB, MaveDB, LitVar.
Notable CYP51A1 variants
Examples include A2P, A2V, A3V, A5P, A5T, L8V, L9P, Q14L. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- A2P (p.Ala2Pro), TOPMed rs1819998665
- A2V (p.Ala2Val), NCI-TCGA Cosmic COSV5015, REVEL 0.08, MetaLR 0.23, Variant assessed as somatic; moderate impact.
- A3V (p.Ala3Val), TOPMed rs1819998530, REVEL 0.03, MetaLR 0.21, Uncertain significance, not specified
- A5P (p.Ala5Pro), TOPMed rs312262909, gnomAD rs312262909
- A5T (p.Ala5Thr), TOPMed rs312262909, gnomAD rs312262909, REVEL 0.06, MetaLR 0.44
- L8V (p.Leu8Val), ExAC rs759186637, gnomAD rs759186637, REVEL 0.08, MetaLR 0.10
- L9P (p.Leu9Pro), ExAC rs765891268, gnomAD rs765891268, REVEL 0.10, MetaLR 0.14
- Q14L (p.Gln14Leu), gnomAD rs1257617460, REVEL 0.27, MetaLR 0.13
- A15V (p.Ala15Val), rs138006785, ClinGen CA4338700, ClinVar RCV003969822, ClinVar RCV005933499, REVEL 0.06, MetaLR 0.11, Likely benign, CYP51A1-related disorder
- G16R (p.Gly16Arg), ExAC rs770354825
- G16V (p.Gly16Val), rs1370167546, ClinGen CA368183158, ClinVar RCV004370606, TOPMed rs1370167546, REVEL 0.19, MetaLR 0.11, Uncertain significance, not specified
- G17A (p.Gly17Ala), ExAC rs777085204, TOPMed rs777085204, gnomAD rs777085204, REVEL 0.08, MetaLR 0.11, Uncertain significance, not provided; not specified
- G17E (p.Gly17Glu), ExAC rs777085204, TOPMed rs777085204, gnomAD rs777085204, REVEL 0.04, MetaLR 0.12, Uncertain significance, not specified
- S18* (p.Ser18Ter), ExAC rs769042342, TOPMed rs769042342, gnomAD rs769042342, CADD 35.00
- S18A (p.Ser18Ala), gnomAD rs1006063551, REVEL 0.06, MetaLR 0.11
- S18W (p.Ser18Trp), ExAC rs769042342, TOPMed rs769042342, gnomAD rs769042342, REVEL 0.19, MetaLR 0.17
- V19A (p.Val19Ala), rs2229188, UniProt VAR 023470, ExAC rs2229188, gnomAD rs2229188, REVEL 0.10, MetaLR 0.13
- Q22H (p.Gln22His), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- Q22K (p.Gln22Lys), rs1819996040, ClinGen CA368183062, ClinVar RCV004351126, ClinVar RCV006561494, REVEL 0.04, MetaLR 0.12, Uncertain significance, not specified; not provided
- A23T (p.Ala23Thr), gnomAD rs1434418422, REVEL 0.04, MetaLR 0.13
- M24I (p.Met24Ile), ExAC rs745869732, TOPMed rs745869732, gnomAD rs745869732, REVEL 0.07, MetaLR 0.13
- M24L (p.Met24Leu), rs772192197, ClinGen CA4338693, ClinVar RCV004352179, ExAC rs772192197, REVEL 0.10, MetaLR 0.09, Uncertain significance, not specified
- K26N (p.Lys26Asn), TOPMed rs1179748917, gnomAD rs1179748917, REVEL 0.04, MetaLR 0.14
- K26R (p.Lys26Arg), rs1232419052, ClinGen CA368182967, ClinVar RCV004268049, TOPMed rs1232419052, REVEL 0.07, MetaLR 0.10, Uncertain significance, not specified
- V27E (p.Val27Glu), rs777701358, ClinGen CA4338691, ClinVar RCV004116113, ExAC rs777701358, AlphaMissense 0.16, MetaLR 0.15, Uncertain significance, not specified
- G30S (p.Gly30Ser), Ensembl rs1819995214, REVEL 0.07, MetaLR 0.11
- N31I (p.Asn31Ile), TOPMed rs1819995143
- N31K (p.Asn31Lys), 1000Genomes rs146964281, ESP rs146964281, ExAC rs146964281, TOPMed rs146964281, MetaLR 0.10, MetaSVM -1.03, Likely benign
- N31S (p.Asn31Ser), TOPMed rs1819995143, REVEL 0.12, MetaLR 0.10
- L32F (p.Leu32Phe), TOPMed rs1819994970, gnomAD rs1819994970, REVEL 0.20, MetaLR 0.15
- L32H (p.Leu32His), Ensembl rs1563183392, REVEL 0.41, MetaLR 0.14
- L33S (p.Leu33Ser), ExAC rs754634511, TOPMed rs754634511, gnomAD rs754634511, REVEL 0.25, MetaLR 0.14
- L33V (p.Leu33Val), NCI-TCGA Cosmic COSV5015, Variant assessed as somatic; moderate impact.
- M35I (p.Met35Ile), ExAC rs751210534, gnomAD rs751210534, REVEL 0.09, MetaLR 0.13
- M35L (p.Met35Leu), gnomAD rs1278131014, REVEL 0.13, MetaLR 0.08
- L36R (p.Leu36Arg), ExAC rs765867586
- L37P (p.Leu37Pro), gnomAD rs1278512464
- L37V (p.Leu37Val), ExAC rs762525937, gnomAD rs762525937, REVEL 0.35, MetaLR 0.28
- I38T (p.Ile38Thr), Ensembl rs1584641083, MetaLR 0.13, MetaSVM -0.97
- A39S (p.Ala39Ser), ExAC rs749892526, TOPMed rs749892526, gnomAD rs749892526, REVEL 0.07, MetaLR 0.15
- A39T (p.Ala39Thr), ExAC rs749892526, TOPMed rs749892526, gnomAD rs749892526
- C40G (p.Cys40Gly), gnomAD rs1414578203, REVEL 0.18, MetaLR 0.14
- C40S (p.Cys40Ser), ExAC rs765865740, TOPMed rs765865740, gnomAD rs765865740, REVEL 0.12, MetaLR 0.10
- A41T (p.Ala41Thr), ESP rs376664914, ExAC rs376664914, gnomAD rs376664914, REVEL 0.04, MetaLR 0.13
- T43P (p.Thr43Pro), Ensembl rs1584641051
- L44P (p.Leu44Pro), TOPMed rs1819992987
- S45N (p.Ser45Asn), NCI-TCGA TCGA novel, MetaLR 0.17, MetaSVM -0.92, Variant assessed as somatic; moderate impact.
- S45T (p.Ser45Thr), Ensembl rs917785462, REVEL 0.08, MetaLR 0.16
- L46Q (p.Leu46Gln), Ensembl rs1055251841, REVEL 0.47, MetaLR 0.22
- Y48H (p.Tyr48His), Ensembl rs1819992574, REVEL 0.47, MetaLR 0.19
- I50F (p.Ile50Phe), Ensembl rs2130961116
- R51C (p.Arg51Cys), ExAC rs772128272, gnomAD rs772128272, REVEL 0.27, MetaLR 0.17
- R51H (p.Arg51His), ESP rs141141306, ExAC rs141141306, TOPMed rs141141306, gnomAD rs141141306, REVEL 0.25, MetaLR 0.14
- R51S (p.Arg51Ser), ExAC rs772128272, gnomAD rs772128272, REVEL 0.27, MetaLR 0.14
- L52V (p.Leu52Val), ExAC rs778926494, TOPMed rs778926494, gnomAD rs778926494
- A54T (p.Ala54Thr), ESP rs372343694, ExAC rs372343694, TOPMed rs372343694, gnomAD rs372343694, REVEL 0.05, AlphaMissense 0.20
- A54V (p.Ala54Val), gnomAD rs1217673079, REVEL 0.09, MetaLR 0.09
- H56Q (p.His56Gln), rs1283391141, ClinGen CA368182433, ClinVar RCV004095740, gnomAD rs1283391141, REVEL 0.10, MetaLR 0.12, Uncertain significance, not specified
- H56Y (p.His56Tyr), ExAC rs573353670, TOPMed rs573353670, gnomAD rs573353670, REVEL 0.16, MetaLR 0.12, Uncertain significance, not specified
- V58A (p.Val58Ala), Ensembl rs1819991093, MetaLR 0.08, MetaSVM -0.99
- L60M (p.Leu60Met), gnomAD rs1293347153, REVEL 0.14, AlphaMissense 0.08
- L60R (p.Leu60Arg), Ensembl rs1819990747
- P61L (p.Pro61Leu), TOPMed rs1232344451, gnomAD rs1232344451, REVEL 0.19, MetaLR 0.17
- A62S (p.Ala62Ser), ExAC rs779766189, TOPMed rs779766189, gnomAD rs779766189, REVEL 0.05, AlphaMissense 0.09
- A62T (p.Ala62Thr), ExAC rs779766189, TOPMed rs779766189, gnomAD rs779766189
- G63E (p.Gly63Glu), ExAC rs376480367, TOPMed rs376480367, gnomAD rs376480367, REVEL 0.11, MetaLR 0.12
- G63W (p.Gly63Trp), gnomAD rs1411606857, REVEL 0.28, AlphaMissense 0.11
- V64M (p.Val64Met), rs1194909981, NCI-TCGA Cosmic COSV9913, TOPMed rs1194909981, AlphaMissense 0.10, MetaLR 0.12, Variant assessed as somatic; moderate impact.
- K65E (p.Lys65Glu), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- K65R (p.Lys65Arg), gnomAD rs1461734631, REVEL 0.26, MetaLR 0.31
- S66G (p.Ser66Gly), rs1352969867, ClinGen CA368181416, ClinVar RCV002036701, ClinVar RCV004897732, REVEL 0.16, MetaLR 0.26, Uncertain significance, not provided; not specified
- P68L (p.Pro68Leu), Ensembl rs1819927610, REVEL 0.92, MetaLR 0.91
- P68S (p.Pro68Ser), NCI-TCGA TCGA novel, MetaLR 0.91, MetaSVM 1.03, Variant assessed as somatic; moderate impact.
- P68T (p.Pro68Thr), gnomAD rs1168081018, REVEL 0.94, MetaLR 0.91
- Y69* (p.Tyr69Ter), ExAC rs774551272, TOPMed rs774551272, gnomAD rs774551272, CADD 37.00
- Y69C (p.Tyr69Cys), NCI-TCGA Cosmic COSV9913, MetaLR 0.38, MetaSVM -0.49, Variant assessed as somatic; moderate impact.
- I70V (p.Ile70Val), ExAC rs766521402, gnomAD rs766521402, REVEL 0.37, MetaLR 0.28
- F71L (p.Phe71Leu), gnomAD rs1819927319, REVEL 0.20, MetaLR 0.22
- F71V (p.Phe71Val), ExAC rs763030715, gnomAD rs763030715, REVEL 0.18, MetaLR 0.16
- S72F (p.Ser72Phe), ExAC rs773113914, gnomAD rs773113914, REVEL 0.83, MetaLR 0.75
- P73A (p.Pro73Ala), TOPMed rs1819927122
- I74F (p.Ile74Phe), 1000Genomes rs148197561, ESP rs148197561, ExAC rs148197561, TOPMed rs148197561, REVEL 0.39, MetaLR 0.21
- I74L (p.Ile74Leu), 1000Genomes rs148197561, ESP rs148197561, ExAC rs148197561, TOPMed rs148197561, REVEL 0.13, MetaLR 0.16
- I74V (p.Ile74Val), 1000Genomes rs148197561, ESP rs148197561, ExAC rs148197561, TOPMed rs148197561, REVEL 0.09, MetaLR 0.19
- F76L (p.Phe76Leu), Ensembl rs1375875402, REVEL 0.39, MetaLR 0.20
- F76Y (p.Phe76Tyr), gnomAD rs1230760264, REVEL 0.40, MetaLR 0.26
- L77F (p.Leu77Phe), gnomAD rs1213473126, REVEL 0.29, MetaLR 0.35
- G78V (p.Gly78Val), ExAC rs771992136, gnomAD rs771992136, REVEL 0.94, MetaLR 0.90
- H79Y (p.His79Tyr), ESP rs375716835, ExAC rs375716835, TOPMed rs375716835, gnomAD rs375716835, REVEL 0.48, MetaLR 0.27
- A80D (p.Ala80Asp), NCI-TCGA Cosmic COSV9913, REVEL 0.78, MetaLR 0.59, Variant assessed as somatic; moderate impact.
- F83L (p.Phe83Leu), gnomAD rs1280033473, REVEL 0.94, MetaLR 0.67
- G84E (p.Gly84Glu), Ensembl rs868830240
- K85E (p.Lys85Glu), Ensembl rs1819926502, REVEL 0.15, MetaLR 0.24
- S86C (p.Ser86Cys), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- I88T (p.Ile88Thr), ESP rs149112643, ExAC rs149112643, TOPMed rs149112643, gnomAD rs149112643, REVEL 0.69, MetaLR 0.69
- I88V (p.Ile88Val), rs138205508, ClinGen CA4338630, ClinVar RCV002121569, 1000Genomes rs138205508, REVEL 0.30, MetaLR 0.41, Likely benign, not provided
- E89K (p.Glu89Lys), NCI-TCGA Cosmic COSV5015, REVEL 0.18, MetaLR 0.15, Variant assessed as somatic; moderate impact.
- E92G (p.Glu92Gly), TOPMed rs1034741279, MetaLR 0.17, MetaSVM -0.86
- E92Q (p.Glu92Gln), Ensembl rs1819926215, REVEL 0.22, MetaLR 0.17
- N93K (p.Asn93Lys), TOPMed rs1206256829, gnomAD rs1206256829, REVEL 0.07, MetaLR 0.13
- A94T (p.Ala94Thr), rs1819926035, ClinGen CA368180826, ClinVar RCV001775023, Ensembl rs1819926035, REVEL 0.43, MetaLR 0.53, Uncertain significance, Developmental cataract
- E96* (p.Glu96Ter), Ensembl rs2130958012, CADD 42.00
- E96G (p.Glu96Gly), rs756695149, ClinGen CA4338626, ClinVar RCV002601876, ExAC rs756695149, REVEL 0.40, MetaLR 0.29, Uncertain significance, not provided
- E96K (p.Glu96Lys), NCI-TCGA Cosmic COSV5015, REVEL 0.10, MetaLR 0.15, Variant assessed as somatic; moderate impact.
- K97* (p.Lys97Ter), NCI-TCGA Cosmic COSV5015, Variant assessed as somatic; high impact.
- K97N (p.Lys97Asn), NCI-TCGA Cosmic COSV9913, REVEL 0.67, MetaLR 0.60, Variant assessed as somatic; moderate impact.
- Y98C (p.Tyr98Cys), ExAC rs755424289, TOPMed rs755424289, gnomAD rs755424289, REVEL 0.86, MetaLR 0.53
- S103G (p.Ser103Gly), ExAC rs780364458, gnomAD rs780364458, REVEL 0.70, AlphaMissense 0.04
- F104C (p.Phe104Cys), TOPMed rs957151238, gnomAD rs957151238, REVEL 0.85, AlphaMissense 0.55
- T105N (p.Thr105Asn), ExAC rs750608351, gnomAD rs750608351, REVEL 0.29, MetaLR 0.24
- T105S (p.Thr105Ser), ExAC rs750608351, gnomAD rs750608351, REVEL 0.31, MetaLR 0.23
- M106V (p.Met106Val), rs146474563, ClinGen CA4338587, ClinVar RCV003387616, ESP rs146474563, AlphaMissense 0.29, MetaLR 0.44, Uncertain significance, not provided
- V107A (p.Val107Ala), rs1275196515, NCI-TCGA Cosmic COSV5015, cosmic curated COSV50152, TOPMed rs1275196515, REVEL 0.13, AlphaMissense 0.88, Variant assessed as somatic; moderate impact.
- V107I (p.Val107Ile), 1000Genomes rs551704866, ExAC rs551704866, TOPMed rs551704866, gnomAD rs551704866, REVEL 0.19, MetaLR 0.32, Uncertain significance, not specified
- T110A (p.Thr110Ala), Ensembl rs977139484
- T112S (p.Thr112Ser), rs759517992, ClinGen CA4338583, ClinVar RCV004370605, ExAC rs759517992, REVEL 0.85, MetaLR 0.81, Uncertain significance, not specified
- L114P (p.Leu114Pro), gnomAD rs1242380745, REVEL 0.81, MetaLR 0.51
- L115P (p.Leu115Pro), TOPMed rs1328030760, gnomAD rs1328030760, REVEL 0.85, MetaLR 0.66, Uncertain significance
- L115R (p.Leu115Arg), rs1328030760, ClinGen CA368179647, ClinVar RCV004287454, TOPMed rs1328030760, REVEL 0.93, MetaLR 0.78, Uncertain significance, not specified
- G116V (p.Gly116Val), cosmic curated COSV50152, TOPMed rs1819865693, REVEL 0.94, MetaLR 0.85, Uncertain significance, not provided
- D118A (p.Asp118Ala), 1000Genomes rs528523424, ExAC rs528523424, TOPMed rs528523424, gnomAD rs528523424, REVEL 0.44, MetaLR 0.45
- D118V (p.Asp118Val), 1000Genomes rs528523424, ExAC rs528523424, TOPMed rs528523424, gnomAD rs528523424, REVEL 0.76, MetaLR 0.66
- A119G (p.Ala119Gly), gnomAD rs1381645352, REVEL 0.31, MetaLR 0.28
- A120V (p.Ala120Val), ExAC rs770839295, gnomAD rs770839295, MetaLR 0.24, MetaSVM -0.50
- A121P (p.Ala121Pro), ExAC rs762730609, TOPMed rs762730609, gnomAD rs762730609
- A121T (p.Ala121Thr), ExAC rs762730609, TOPMed rs762730609, gnomAD rs762730609, REVEL 0.12, MetaLR 0.22
- A121V (p.Ala121Val), ESP rs375807424, ExAC rs375807424, gnomAD rs375807424, REVEL 0.29, MetaLR 0.37
- L122R (p.Leu122Arg), Ensembl rs1819865227
- N125H (p.Asn125His), ESP rs372875744, ExAC rs372875744, TOPMed rs372875744, gnomAD rs372875744, REVEL 0.61, MetaLR 0.52
- S126N (p.Ser126Asn), ExAC rs780640460, gnomAD rs780640460, MetaLR 0.51, MetaSVM 0.10
- D130E (p.Asp130Glu), ExAC rs747490076, TOPMed rs747490076, gnomAD rs747490076, REVEL 0.11, MetaLR 0.20
- D130H (p.Asp130His), cosmic curated COSV10581, TOPMed rs1374029916, gnomAD rs1374029916, REVEL 0.60, MetaLR 0.50
- A133S (p.Ala133Ser), TOPMed rs1819864606
- A133T (p.Ala133Thr), TOPMed rs1819864606, REVEL 0.72, MetaLR 0.61
- A133V (p.Ala133Val), Ensembl rs1353246786, MetaLR 0.58, MetaSVM 0.31
- D135G (p.Asp135Gly), TOPMed rs1441644451, gnomAD rs1441644451, REVEL 0.44, MetaLR 0.36
- D135Y (p.Asp135Tyr), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- Y137C (p.Tyr137Cys), ESP rs368261783, ExAC rs368261783, TOPMed rs368261783, gnomAD rs368261783, MetaLR 0.40, MetaSVM 0.09
- S138N (p.Ser138Asn), ExAC rs750743669, gnomAD rs750743669, REVEL 0.18, MetaLR 0.27
- R139C (p.Arg139Cys), rs758553106, ClinGen CA4338570, ClinVar RCV003702257, ExAC rs758553106, REVEL 0.44, MetaLR 0.46, Uncertain significance, not provided
- R139H (p.Arg139His), cosmic curated COSV50151, ESP rs140356336, ExAC rs140356336, TOPMed rs140356336, REVEL 0.06, MetaLR 0.13
- R139L (p.Arg139Leu), ESP rs140356336, ExAC rs140356336, TOPMed rs140356336, gnomAD rs140356336, REVEL 0.34, MetaLR 0.33
- T142I (p.Thr142Ile), TOPMed rs1819863942, MetaLR 0.35, MetaSVM -0.18
- P143S (p.Pro143Ser), gnomAD rs1340319542, REVEL 0.84, MetaLR 0.82
- V144M (p.Val144Met), Ensembl rs898646402, REVEL 0.78, MetaLR 0.76
- A150G (p.Ala150Gly), TOPMed rs1819863457, gnomAD rs1819863457, REVEL 0.56, MetaLR 0.44
- A150T (p.Ala150Thr), NCI-TCGA Cosmic COSV9913, cosmic curated COSV99134, Variant assessed as somatic; moderate impact.
- A150V (p.Ala150Val), TOPMed rs1819863457, gnomAD rs1819863457, MetaLR 0.25, MetaSVM -0.72
- Y151C (p.Tyr151Cys), Ensembl rs1819863354, MetaLR 0.59, MetaSVM 0.44
- Y151D (p.Tyr151Asp), TOPMed rs312262912, gnomAD rs312262912, REVEL 0.85, MetaLR 0.59
- D152E (p.Asp152Glu), ExAC rs766350147, gnomAD rs766350147, REVEL 0.58, MetaLR 0.52
- D152G (p.Asp152Gly), ESP rs371492794, ExAC rs371492794, TOPMed rs371492794, gnomAD rs371492794, REVEL 0.86, MetaLR 0.49
- D152H (p.Asp152His), ExAC rs755026542, TOPMed rs755026542, gnomAD rs755026542
- D152N (p.Asp152Asn), cosmic curated COSV50151, ExAC rs755026542, TOPMed rs755026542, gnomAD rs755026542, REVEL 0.68, MetaLR 0.62, Uncertain significance, not provided
- P154L (p.Pro154Leu), ExAC rs762665681, TOPMed rs762665681, gnomAD rs762665681, REVEL 0.87, MetaLR 0.80
- P154T (p.Pro154Thr), gnomAD rs1320973894, REVEL 0.78, MetaLR 0.75
- N155S (p.Asn155Ser), gnomAD rs1396756852, REVEL 0.66, MetaLR 0.74
- P156L (p.Pro156Leu), ESP rs146573154, ExAC rs146573154, TOPMed rs146573154, gnomAD rs146573154, REVEL 0.40, MetaLR 0.60
- V157A (p.Val157Ala), gnomAD rs1363459886, REVEL 0.30, MetaLR 0.35
- V157F (p.Val157Phe), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- V157G (p.Val157Gly), gnomAD rs1363459886, MetaLR 0.45, MetaSVM 0.01
- V157I (p.Val157Ile), cosmic curated COSV10720, ExAC rs766245719, gnomAD rs766245719, REVEL 0.06, MetaLR 0.13
- F158L (p.Phe158Leu), Ensembl rs1819827676, REVEL 0.41, MetaLR 0.21
- F158V (p.Phe158Val), gnomAD rs1180347451, MetaLR 0.17, MetaSVM -1.00
- M164L (p.Met164Leu), 1000Genomes rs144068591, ExAC rs144068591, TOPMed rs144068591, gnomAD rs144068591, REVEL 0.21, MetaLR 0.25, Uncertain significance, not provided
- M164R (p.Met164Arg), TOPMed rs1819827472, gnomAD rs1819827472, MetaLR 0.25, MetaSVM -0.69
- L165* (p.Leu165Ter), ExAC rs750224776, gnomAD rs750224776, CADD 36.00
- L165V (p.Leu165Val), TOPMed rs1819827371
- S167G (p.Ser167Gly), rs1441786183, ClinGen CA368178022, cosmic curated COSV50152, ClinVar RCV004125279, REVEL 0.27, MetaLR 0.32, Uncertain significance, not specified
- S167T (p.Ser167Thr), TOPMed rs1819827072, MetaLR 0.23, MetaSVM -0.84
- L169I (p.Leu169Ile), NCI-TCGA Cosmic COSV9913, cosmic curated COSV99133, Variant assessed as somatic; moderate impact.
- L169V (p.Leu169Val), gnomAD rs1225000839, REVEL 0.77, MetaLR 0.83
- N170D (p.Asn170Asp), Ensembl rs2130953382, REVEL 0.48, MetaLR 0.56
- I171M (p.Ile171Met), NCI-TCGA TCGA novel, REVEL 0.61, MetaLR 0.60, Variant assessed as somatic; moderate impact.
- I171V (p.Ile171Val), rs139239552, ClinGen CA4338541, ClinVar RCV002967339, ESP rs139239552, REVEL 0.26, MetaLR 0.42, Uncertain significance, not provided
- A172T (p.Ala172Thr), gnomAD rs1819826530, REVEL 0.09, MetaLR 0.21
- A172V (p.Ala172Val), ExAC rs776271983, TOPMed rs776271983, gnomAD rs776271983, REVEL 0.16, MetaLR 0.20
- Q176L (p.Gln176Leu), NCI-TCGA TCGA novel, MetaLR 0.23, MetaSVM -0.78, Variant assessed as somatic; moderate impact.
- H177Q (p.His177Gln), TOPMed rs1400566855, MetaLR 0.51, MetaSVM 0.02
- H177R (p.His177Arg), TOPMed rs535433995, gnomAD rs535433995, REVEL 0.39, MetaLR 0.36
Public CYP51A1 analysis runs
- CYP51A1 analysis run — CYP51A1 (761 variants) — completed 2026-07-17